Navigation Links
Two ISPE Studies Cited in FDA Statement to Congress
Date:12/20/2013

Tampa, Fla. USA (PRWEB) December 20, 2013

Two recent ISPE studies were cited by Janet Woodcock, M.D., Director of the US FDA’s Center for Drug Evaluation and Research (CDER), in her statement associated with her testimony to the U.S. Congressional Committee on Oversight and Government Reform’s Subcommittee on Energy Policy, Health Care and Entitlements.

In the December 12 hearing, “FDA Check Up: Drug Development and Manufacturing Challenges,” Dr. Woodcock stated that novel manufacturing technologies could, with the proper strategies, revitalize pharmaceutical manufacturing in the U.S., thereby reducing dependence on potentially vulnerable foreign-sourced materials. Dr. Woodcock reported that the FDA has been working in collaboration with industry experts to stimulate the development of new manufacturing technologies capable of responding rapidly to changes in demand.

During her testimony, Dr. Woodcock strongly advocated the use of Quality by Design (QbD) to enhance development capability and reduce manufacturing costs while ensuring that patients receive high-quality drug products. As evidence, Dr. Woodcock cited the results of a survey conducted by the ISPE United Kingdom Affiliate’s Process Analytical Technology (PAT) Community of Practice, in which companies using QbD reported benefits such as improved product quality and process robustness, increased process capability, greater speed and reliability to market, as well as significant cost benefits.

QbD also can increase manufacturing capability and a firm’s ability to identify the root causes of manufacturing failures, said Dr. Woodcock, referencing ISPE’s Drug Shortages study and naming inadequate manufacturing capability as a frequent cause of critical drug supply shortfalls, particularly in the areas of lyophilization (freeze-drying) associated with the production of sterile products.

“We applaud the FDA’s collaborative approach to the development of new manufacturing technologies as a means of ensuring the availability of safe and effective medicines,” said Nancy S. Berg, President and CEO of ISPE. “The development and adoption of new and novel manufacturing technologies such as continuous manufacturing requires close collaboration and communication between the pharmaceutical industry and global regulators. As a neutral organization focused on product quality important to patient safety, we are pleased to provide the FDA with reliable, authoritative, scientific technical data and experience. We look forward to continued collaboration with the FDA to modernize manufacturing methods.”

Published in June 2013, ISPE’s Drug Shortages Survey report is available at http://www.ISPE.org/Drug-Shortages/2013JuneReport. The report also was cited in the FDA’s Strategic Plan for Preventing and Mitigating Drug Shortages published in October. ISPE plans to deliver additional updates during 2014.

A summary of the Business Benefits of Quality by Design (QbD) survey conducted by the ISPE United Kingdom Affiliate’s PAT Community of Practice was published in the July-August 2012 issue of Pharmaceutical Engineering magazine.
###

Read the full story at http://www.prweb.com/releases/2013/12/prweb11441492.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
2. Elsevier Announces the Launch of Open Access Journal: Case Studies in Construction Materials
3. Associates for Breast and Prostate Cancer Studies Honors Ann-Margret, Robert Wagner and Bill and Roseann Patterson at 24th Annual The Talk of the Town Gala
4. Successful Pediatric Studies: Key Study Design and Operational Considerations, a New Webinar Presented by Premier Research and Xtalks
5. Enteroviruses Cause Type 1 Diabetes; New Studies Support Dr. Hanan Polansky’s Microcompetition Theory
6. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
7. Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
8. Sciedu Press Launches New Journal for Management and Orgnaization Studies
9. Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies
10. AACC Pilot Studies Begin to Measure What Is Normal in Childrens Development
11. Addressing Scientific and Regulatory Challenges for Abuse Liability Studies, New Life Science Webinar Hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017 On Thursday, March 23, ... 5,817.69, down 0.07%; the Dow Jones Industrial Average edged ... 500 closed at 2,345.96, marginally dropping 0.11%. US markets ... green, 4 sectors finished in red, and 1 sector ... initiated reports coverage on the following Biotechnology equities: BioDelivery ...
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... selected by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® ... annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in ...
(Date:3/23/2017)... -- In today,s pre-market research, Stock-Callers.com takes ... industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals Inc. ... Regulus Therapeutics Inc. (NASDAQ: RGLS ). On ... rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more about ... ...
Breaking Biology Technology:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):